We report the results of a second nationwide survey aimed at clarifying the clinical course of rhododenol-induced leukoderma. The survey was performed between December 2013 and January 2014, and 1,445 cases were analyzed. With regard to outcome, 72% of the cases were comprehensively evaluated as slightly improved, improved, or cured. In 42% of the cases, we observed hyperpigmentation in the depigmented area or in the surrounding area during the disease course. Among the cases, 56.9% were treated with topical medicaments, oral medicines, or ultraviolet light irradiation, the latter was particularly effective.
During treatment with anti-epidermal growth factor receptor antibody, skin disorders are considered major adverse drug reactions. Clinical features of skin disorders during panitumumab (Pmab) treatment for wild-type KRAS gene unresectable, advanced or recurrent colorectal cancer were analyzed as a post hoc analysis of a post-marketing surveillance study for Pmab. Information was collected during clinical courses for 10 months, or until discontinuation of Pmab for any reason. Among 3,085 patients, dermatitis acneiform occurred in 69.9% of the patients, paronychia in 24.2%, dry skin in 21.7%, and pruritus in 4.8%. Among the patients who experienced skin disorders, 6.9% of the patients withdrew from panitumumab therapy because of skin disorders. Topical corticosteroids, oral antibiotics, or emollients were usually administered for treatment of skin disorders. Approximately 80% of the patients with these adverse events recovered or were recovering. The incidence of dermatitis acneiform was significantly higher in males, patients who were <65 years who had heavier body weight, or who took a higher dose per 1 m2 of body surface area.